Hepatic RIG-I Predicts Survival and Interferon-伪 Therapeutic Response in Hepatocellular Carcinoma

详细信息    查看全文

• 作者：Jin Hou ; Ye Zhou ; Yuanyuan Zheng ; Jia Fan ; Weiping Zhou ; Irene聽O.L. Ng ; Huichuan Sun ; Lunxiu Qin ; Shuangjian Qiu ; Joyce聽M.F. Lee ; Chung-Mau Lo ; Kwan Man ; Yuan Yang ; Yun Yang ; Yingyun Yang ; Qian Zhang ; Xuhui Zhu ; Nan Li ; Zhengxin Wang ; Guoshan Ding ; Shi-Mei Zhuang ; et al.
• 刊名：Cancer Cell
• 出版年：13 January, 2014
• 年：2014
• 卷：25
• 期：1
• 页码：49-63
• 全文大小：4055 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Summary

In hepatocellular carcinoma (HCC), biomarkers for prediction of prognosis and response to immunotherapy such as interferon-伪 (IFN-伪) would be very useful in the clinic. We found that expression of retinoic acid-inducible gene-I (RIG-I), an IFN-stimulated gene, was significantly downregulated in human HCC tissues. Patients with low RIG-I expression had shorter survival and poorer response to IFN-伪 therapy, suggesting that RIG-I is a useful prognosis and IFN-伪 response predictor for HCC patients. Mechanistically, RIG-I enhances IFN-伪 response by amplifying IFN-伪 effector signaling via strengthening STAT1 activation. Furthermore, we found that RIG-I deficiency promotes HCC carcinogenesis and that hepatic RIG-I expression is lower in men than in women. RIG-I may therefore be a tumor suppressor in HCC and contribute to HCC gender disparity.